Literature DB >> 25074542

Molecular cytogenetic characterization of mammary neuroendocrine carcinoma.

De-Bing Xiang1, Bing Wei2, Susan C Abraham3, Lei Huo3, Constance T Albarracin3, Hong Zhang3, Gildy Babiera4, Abigail S Caudle4, Catherine L Akay4, Pulivarthi Rao5, Yi-Jue Zhao5, Xinyan Lu6, Yun Wu7.   

Abstract

Primary mammary neuroendocrine carcinoma (NEC) is an uncommon entity that accounts for 2% to 5% of breast carcinomas. Recent reports have shown that NEC of the breast is an aggressive subtype of mammary carcinoma that is distinct from invasive ductal carcinoma, not otherwise specified, and have suggested that these tumors have a poorer prognosis than invasive ductal carcinoma, not otherwise specified. In this study, we provide the first cytogenetic characterization of mammary NEC using both conventional G-banding and spectral karyotype on a group of 7 tumors. We identified clonal chromosomal aberrations in 5 (71.4%) cases, with 4 of them showing complex karyotypes. Of these, recurrent numerical aberrations included gain of chromosome 7 (n = 2) and loss of chromosome 15 (n = 2). Recurrent clonal structural chromosomal aberrations involved chromosomes 1 (n = 3), 3 (n = 2), 6q (n = 3), and 17q (n = 3). Of the 4 (57.1%) cases with complex karyotypes, 2 showed evidence of chromothripsis, a phenomenon in which tens to hundreds of genomic rearrangements occur in a one-off cellular crisis. One of these had evidence of chromothripsis involving chromosomes 1, 6, 8, and 15. The other also had evidence of chromosome 8 chromothripsis, making this a recurrent finding shared by both cases. We also found that mammary NEC shared some cytogenetic abnormalities--such as trisomy 7 and 12--with other neuroendocrine tumors in the lung and gastrointestinal tract, suggesting trisomy 7 and 12 as potential common molecular aberrations in neuroendocrine tumors. To our knowledge, this is the first report on molecular cytogenetic characterization of mammary NEC.
Copyright © 2014 Elsevier Inc. All rights reserved.

Entities:  

Keywords:  Chromothripsis; FISH; Mammary neuroendocrine carcinoma; Molecular cytogenetics; Spectral karyotype

Mesh:

Year:  2014        PMID: 25074542     DOI: 10.1016/j.humpath.2014.06.002

Source DB:  PubMed          Journal:  Hum Pathol        ISSN: 0046-8177            Impact factor:   3.466


  5 in total

1.  A high-quality model for predicting the prognosis of breast neuroendocrine carcinoma to help clinicians decide on appropriate treatment methods: A population-based analysis.

Authors:  Yu-Qiu Chen; Xiao-Fan Xu; Jia-Wei Xu; Tian-Yu Di; Xu-Lin Wang; Li-Qun Huo; Lu Wang; Jun Gu; Guo-Hua Zhou
Journal:  Transl Oncol       Date:  2022-06-11       Impact factor: 4.803

2.  Genome-wide copy number aberrations and HER2 and FGFR1 alterations in primary breast cancer by molecular inversion probe microarray.

Authors:  Hui Chen; Rajesh R Singh; Xinyan Lu; Lei Huo; Hui Yao; Kenneth Aldape; Ronald Abraham; Shumaila Virani; Meenakshi Mehrotra; Bal Mukund Mishra; Alex Bousamra; Constance Albarracin; Yun Wu; Sinchita Roy-Chowdhuri; Rashmi Kanagal-Shamanna; Mark J Routbort; L Jeffrey Medeiros; Keyur P Patel; Russell Broaddus; Aysegul Sahin; Rajyalakshmi Luthra
Journal:  Oncotarget       Date:  2017-02-14

3.  PPM1D Is a Therapeutic Target in Childhood Neural Tumors.

Authors:  Jelena Milosevic; Diana Treis; Susanne Fransson; Gabriel Gallo-Oller; Baldur Sveinbjörnsson; Nina Eissler; Keiji Tanino; Kazuyasu Sakaguchi; Tommy Martinsson; Malin Wickström; Per Kogner; John Inge Johnsen
Journal:  Cancers (Basel)       Date:  2021-11-30       Impact factor: 6.639

4.  Primary neuroendocrine tumour of the breast: a case report and review of the literature.

Authors:  Sara Tato-Varela; Rosa Albalat-Fernández; Sara Pabón-Fernández; Enrique Rodríguez Zarco; Manolo La Calle-Marcos
Journal:  Ecancermedicalscience       Date:  2015-12-22

Review 5.  Neuroendocrine Cancer of the Breast: A Rare Entity.

Authors:  Azzurra Irelli; Maria Maddalena Sirufo; Luca Morelli; Carlo D'Ugo; Lia Ginaldi; Massimo De Martinis
Journal:  J Clin Med       Date:  2020-05-13       Impact factor: 4.241

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.